Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (221-230 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical and Translational Science|December 2, 2024
Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer ControlRobert Schnoll, Justin E Bekelman, Daniel Blumenthal, et al.
Biorxiv : the Preprint Server for Biology|January 3, 2024
Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variantsHuaizhi Huang, Chunling Hu, Jie Na, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Cancer During Pregnancy: Navigating Clinical and Research ChallengesMackenzie K Callaway, Lizelle Comfort, Dhivyaa Anandan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
JCO Precision Oncology|November 4, 2022
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry CompositionElisha Hughes, Susanne Wagner, Dmitry Pruss, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2018
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment SubstudyCristina Cruz, Alba Llop-Guevara, Judy E Garber, et al.
Pageof 37

Showing results (221-230 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical and Translational Science|December 2, 2024
Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer ControlRobert Schnoll, Justin E Bekelman, Daniel Blumenthal, et al.
Biorxiv : the Preprint Server for Biology|January 3, 2024
Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variantsHuaizhi Huang, Chunling Hu, Jie Na, et al.
Medrxiv : the Preprint Server for Health Sciences|August 20, 2025
Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patientsTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Cancer|December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Cancer During Pregnancy: Navigating Clinical and Research ChallengesMackenzie K Callaway, Lizelle Comfort, Dhivyaa Anandan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
JCO Precision Oncology|November 4, 2022
Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry CompositionElisha Hughes, Susanne Wagner, Dmitry Pruss, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2018
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment SubstudyCristina Cruz, Alba Llop-Guevara, Judy E Garber, et al.
Pageof 37